- Former LBBC staff writer and content coordinator
Pembrolizumab approved for high-risk triple-negative breast cancer
The FDA approved the use of pembrolizumab (Keytruda) to treat some early-stage, triple-negative breast cancers, marking the first time an immunotherapy medicine has been approved for use in early-stage breast cancer.
Healthy eating habits you can start right now
There are many ways to make healthier food choices, but it can be hard to know where to start. We spoke to cancer nutrition and fitness expert Stacy Kennedy, MPH, RD, CSO, LDN, CPT, about what you can do if you’ve just resolved to start a healthier diet.
Eight ways to cope with the holidays during a pandemic
For people affected by breast cancer, the holidays can be difficult every year. As experts caution against large events, traveling, and indoor gatherings for the 2020 season, the way we celebrate this year will be different than we are used to, and that can make this time even more upsetting.
ASCO studies explore medicine combinations, order to treat metastatic hormone receptor-positive breast cancer
Two studies, presented as part of the 2020 ASCO Annual Meeting, provide guidance on how medicines approved in the past few years are best used in combination and after other treatments.
PHERGain study suggests some with HER2-positive early breast cancer may not need chemotherapy
The PHERGain trial, presented May 29 as part of the 2020 ASCO Annual Meeting, explored using PET scans to select people with early-stage HER2-positive breast cancer who may not need chemotherapy.
Capecitabine after treatment for early triple-negative breast cancer reduces risk of recurrence
Adding a year of capecitabine (Xeloda) after standard treatment resulted in fewer people with early-stage, triple-negative breast cancer having a recurrence, according to a study presented at the 2020 ASCO Annual Meeting.
Breast cancer treatment during the coronavirus outbreak
Drs. Julie Gralow and Reshma Mahtani explain how people in treatment for breast cancer can balance the known threat of breast cancer against what was known about the potential threat of developing COVID-19 in the first few months of the pandemic.
Adding tucatinib to third-line treatment leads to longer overall survival in people with metastatic, HER2-positive breast cancer
Given with trastuzumab and capecitabine, tucatinib also led to longer progression-free survival and improved outcomes for people with brain metastases.
Allergan Recalls Textured Breast Implants Linked to Rare Cancer
Allergan announced on July 24 that it is voluntarily recalling breast implants with its Biocell textured surface. The implants have been linked to a rare cancer called breast implant-associated anaplastic large cell lymphoma.
CDK 4/6 Inhibitor Ribociclib Improves Overall Survival for Premenopausal Women With Metastatic, Hormone Receptor-Positive Breast Cancer
The addition of the CDK 4/6 inhibitor ribociclib (Kisqali) to hormonal therapy for premenopausal women with metastatic, hormone-receptor positive breast cancer, resulted in women living longer than they would if given hormonal therapy alone.
Biomarker Tests for Early-Stage, Hormone Receptor-Positive Breast Cancers Show Promise, but More Research is Needed
Positive results for new applications of two existing biomarker tests; researchers hope these new ways of applying the tests will help direct treatments to people who need them, and spare people who won’t benefit.
Updates from the 2017 San Antonio Breast Cancer Symposium
The San Antonio Breast Cancer Symposium is a chance for experts and patient advocates from around the world to come together and discuss updates in treatment and care for people with breast cancer. The 40th annual SABCS is being held December 5 – 9, 2017.
FDA approves abemaciclib for certain HR+ metastatic breast cancers
The Food and Drug Administration has approved abemaciclib (Verzenio), both on its own and in combination with fulvestrant (Faslodex), to treat hormone receptor-positive metastatic breast cancers after other treatments have stopped working.
Study Finds People Who Have Breast Cancer Live Longer With Strong Social Support
Women with breast cancer tend to have better outcomes when they have a bigger network of friends, family and other social connections, but different types of social support were important for different women.
Inherited Risk: Genetic Testing Can Bring Answers, and New Questions
Most cancers are caused by mutations that happen during a person’s life. But some mutations pass from parent to child and put people at higher risk for breast cancer. An estimated 5 to 10 percent of breast cancers are linked to mutations on the most well-known breast cancer-associated genes, the BRCA genes.
‘You feel so lost’: Facing breast cancer when you have a mood or anxiety disorder
Stressful life events, like a cancer diagnosis, put people who have been diagnosed with depression or another mood or anxiety disorder at a higher risk of experiencing an episode related to that disorder.
Partial-breast Radiation OK for More People in New ASTRO Guidelines
The American Society for Radiation Oncology (ASTRO) released new guidelines for the use of accelerated partial-breast radiation to treat early-stage breast cancer that opens the door for more people to get this treatment.
The Choice: When Is Chemotherapy the Right Treatment for Breast Cancer?
Chemotherapy is known for causing side effects, from hair loss to nausea to heart damage to neuropathy. Who gets chemotherapy has changed in recent years, but for many people with breast cancer, chemotherapy is still standard treatment.
After DCIS, Some Women Face Lower Quality of Life
A study found that within 2 years of diagnosis, most women who have had DCIS enjoyed a quality of life similar to that of peers who had no cancer. But it also showed a trend to worse mental well-being in younger women shortly after diagnosis and all women 10 or more years after diagnosis.